Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 158 of 6351
-
Can a new drug keep Crohn's disease in check?
Disease control OngoingThe study consists of 4 sub-studies, as follows: * Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in participants with moderately to severely active Crohn's disease (CD) w…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New antibody combo shows promise for tough childhood cancer
Disease control OngoingChildren and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-C…
Phase 2 • Sponsor: Y-mAbs Therapeutics • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Could hepatitis c-infected hearts save lives? new trial aims to find out
Disease control Recruiting nowThis phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
Phase 2 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Immunotherapy plus chemotherapy shows promise in advanced lung cancer trial
Disease control CompletedThe primary objectives of this study are: Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with advanced squamous or nonsquamous non-small cell lung ca…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
Symptom relief CompletedPediQUEST Response proposes a new system of care that expects to improve quality of life in children, adolescents, and young adults with advanced cancer and their parents. The investigators want to learn whether patients that are cared for using PediQUEST Response do in fact feel…
Sponsor: Joanne Wolfe, MD, MPH • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Brain cancer gene therapy trial aims to boost survival
Disease control Recruiting nowStudy to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).
Phase 1/2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Gene therapy offers hope for children with SCID-X1
Disease control Recruiting nowThis is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3 years…
Phase 1/2 • Sponsor: David Williams • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for brain cancer: triple therapy targets deadliest tumor
Disease control OngoingGlioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults. Despite an aggressive multimodality treatment approach including surgery, radiation therapy and chemotherapy, overall survival remains poor. Pembroli…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Massive malawi trial aims to shield kids from typhoid
Vaccine OngoingThis study will evaluate the efficacy of a Typhoid conjugate vaccine (Vi-TCV) in Malawi, Africa among children age 9 months through 12 years. Participants will be randomized in a 1:1 ration to receive the study vaccine or the control vaccine (meningococcal group A conjugate vacci…
Phase 3 • Sponsor: University of Maryland, Baltimore • Aim: Vaccine
Last updated Jun 27, 2026 12:31 UTC
-
Can Lab-Grown skin heal large wounds with better scars?
Disease control CompletedThis phase II trial aims to evaluate the efficacy and safety of EHSG-KF (synonym denovoSkin) in comparison to meshed STSG in adults and children with full-thickness Skin defects.
Phase 2 • Sponsor: CUTISS AG • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Gene therapy aims to fix sickle cell disease from the inside
Disease control OngoingA promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly DNA) from the patient to treat his or her own disease. In gene therapy, the investigators introduce new genetic…
Phase 1 • Sponsor: David Williams • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Sound waves could tame Parkinson's tremors and twitches
Disease control OngoingEvaluate the safety and efficacy of unilateral focused ultrasound pallidotomy using the ExAblate 4000 System in the management of dyskinesia symptoms or motor fluctuations for medication refractory, advanced idiopathic Parkinson's disease.
Sponsor: InSightec • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can a targeted drug make chemotherapy work again for ovarian cancer?
Disease control Stopped earlyThe purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer.
Phase 1/2 • Sponsor: Michael McHale • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: immunotherapy combo under trial
Disease control OngoingThis phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in th…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Immunotherapy combo aims to extend lives in aggressive breast cancer
Disease control CompletedThis study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a targeted drug hit the mark in Hard-to-Treat blood cancers?
Disease control OngoingThis is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.
Phase 1/2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a shorter treatment hold off small HER2-Positive breast cancers?
Disease control Stopped earlyThis phase II trial aims to study the efficacy and safety of 12 weeks adjuvant docetaxel plus trastuzumab in patients with tumors ≤1cm, node-negative, HER2-positive breast cancer.
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Donor immune cells take on Virus-Linked cancer after transplant
Disease control Recruiting nowThe purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after …
Phase 3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Which strategy wins for heart attack patients with multiple blocked arteries?
Disease control OngoingIn patients with acute ST-elevation myocardial infarction (STEMI), 40-60% have multi-vessel disease with an increased cardiovascular morbidity and mortality. Although it is not recommended to revascularize noninfarct lesions during the acute intervention, recent investigations su…
Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Four-Drug cocktail tame a tough breast cancer?
Disease control OngoingThis is a multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab is proposed as first-line therapy in metastatic hormone receptor-positive, HER2-positive breast cancer patients. In this phase I/II clinical trial, the researchers aim to establish th…
Phase 1/2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC